Purpose UGT2B17 is a vital member of the UGT2 family and functions as a detoxification enzyme which catalyzes the glucuronidation of lipophilic compounds. Accumulating evidences implicates that it may contribute to the susceptibility of tumor risk. Identification of a UGT2B17 deletion polymorphism has attracted studies to evaluate the association between the UGT2B17 deletion polymorphism and tumor risk in diverse populations. However, the available results are conflicting. Methods A meta-analysis based on 14 studies from 10 publications including 5,732 cases and 5,112 controls was performed. Published literature from PubMed, EMBASE and Web of Science was pooled and the crude odds ratios (ORs) with 95% confidence intervals (CIs) were calculated to estimate the strength of the associations. Results Conclusively, our results indicate that individuals with a UGT2B17 deletion polymorphism were associated with tumor risks (OR = 1.29, 95% CI = 1.03–1.63, P<0.001) in a recessive model. However, after excluding two studies for their heterogeneity, the result then demonstrated that the UGT2B17 deletion polymorphism was not associated with tumor risks (OR = 1.118, 95%CI = 0.938–1.332, P>0.1). A subgroup analysis based on tumor type, sex or race did not show significant results. Conclusion These results suggest that the UGT2B17 deletion polymorphism is not associated with tumor risks.
Gallagher CJ, Kadlubar FF, Muscat JE, Ambrosone CB, Lang NP, et al. (2007) The UGT2B17 gene deletion polymorphism and risk of prostate tumor. A case-control study in Caucasians. Tumor Detect Prev 31(4): 310–5.
[3]
Gronberg H (2003) Prostate tumor epidemiology. Lancet 361(9360): 859–64.
[4]
Guillemette C (2003) Pharmacogenomics of human UDP-glucuronosyltransferase enzymes. Pharmacogenomics J 3(3): 136–58.
[5]
Nagar S, Remmel RP (2006) Uridine diphosphoglucuronosyltransferase pharmacogenetics and tumor. Oncogene 25(11): 1659–72.
[6]
Guéraud F, Paris A (1998) Glucuronidation: a dual control. Gen Pharmacol, 31(5): p. 683–8.
[7]
Ren Q, Murphy SE, Zheng Z, Lazarus P (2000) O-Glucuronidation of the lung carcinogen 4-(methylnitrosamino)-1- (3-pyridyl)-1-butanol (NNAL) by human UDP-glucuronosyltransferases 2B7 and 1A9. Drug Metab Dispos 28(11): 1352–60.
[8]
Tephly TR, Burchell B (1990) UDP-glucuronosyltransferases: a family of detoxifying enzymes. Trends Pharmacol Sci, 11(7): p. 276–9.
[9]
Gruber M, Bellemare J, Hoermann G, Gleiss A, Porpaczy E, et al.. (2013) Overexpression of uridine diphospho glucuronosyltransferase 2B17 in high-risk chronic lymphocytic leukemia. Blood, 121(7): p. 1175–83.
[10]
Zheng Z, Fang JL, Lazarus P (2002) Glucuronidation: an important mechanism for detoxification of benzo[a]pyrene metabolites in aerodigestive tract tissues. Drug Metab Dispos 30(4): 397–403.
[11]
Gallagher CJ, Muscat JE, Hicks AN, Zheng Y, Dyer AM, et al. (2007) The UDP-glucuronosyltransferase 2B17 gene deletion polymorphism: sex-specific association with urinary 4-(methylnitrosamino)-1-(3-pyridyl)-1-bu？tanolglucuronidation phenotype and risk for lung tumor. Tumor Epidemiol Biomarkers Prev 16(4): 823–8.
[12]
Wilson W 3rd, Pardo-Manuel de Villena F, Lyn-Cook BD, Chatterjee PK, Bell TA, et al. (2004) Characterization of a common deletion polymorphism of the UGT2B17 gene linked to UGT2B15. Genomics 84(4): 707–14.
[13]
Swanson C, Mellstr？m D, Lorentzon M, Vandenput L, Jakobsson J, et al. (2007) The uridine diphosphate glucuronosyltransferase 2B15 D85Y and 2B17 deletion polymorphisms predict the glucuronidation pattern of androgens and fat mass in men. J Clin Endocrinol Metab 92(12): 4878–82.
[14]
Lazarus P, Zheng Y, Runkle EA, Muscat JE, Wiener D (2005) Genotype-phenotype correlation between the polymorphic UGT2B17 gene deletion and NNAL glucuronidation activities in human liver microsomes. Pharmacogenet Genomics 15(11): 769–78.
[15]
Terakura S, Murata M, Nishida T, Emi N, Akatsuka Y, et al. (2005) A UGT2B17-positive donor is a risk factor for higher transplant-related mortality and lower survival after bone marrow transplantation. Br J Haematol 129(2): 221–8.
[16]
Park J, Chen L, Ratnashinge L, Sellers TA, Tanner JP, et al. (2006) Deletion polymorphism of UDP-glucuronosyltransferase 2B17 and risk of prostate tumor in African American and Caucasian men. Tumor Epidemiol Biomarkers Prev 15(8): 1473–8.
[17]
Park JY, Tanner JP, Sellers TA, Huang Y, Stevens CK, et al. (2007) Association between polymorphisms in HSD3B1 and UGT2B17 and prostate tumor risk. Urology 70(2): 374–9.
[18]
Karypidis AH, Olsson M, Andersson SO, Rane A, Ekstr？m L, et al. (2008) Deletion polymorphism of the UGT2B17 gene is associated with increased risk for prostate tumor and correlated to gene expression in the prostate. Pharmacogenomics J 8(2): 147–51.
[19]
Olsson M, Lindstr？m S, H？ggkvist B, Adami HO, B？lter K, et al. (2008) The UGT2B17 gene deletion is not associated with prostate tumor risk. Prostate 68(5): 571–5.
[20]
Setlur SR, Chen CX, Hossain RR, Ha JS, Van Doren VE, et al. (2010) Genetic variation of genes involved in dihydrotestosterone metabolism and the risk of prostate tumor. Tumor Epidemiol Biomarkers Prev 19(1): 229–39.
[21]
Gruber M, Le T, Filipits M, Gsur A, Mannhalter C, et al. (2013) UDP-glucuronosyltransferase 2B17 genotype and the risk of lung tumor among Austrian Caucasians. Tumor Epidemiol 37(5): 625–8.
[22]
Eskandari-Nasab E, Hashemi M, Rezaei H, Fazaeli A, Mashhadi MA, et al. (2012) Evaluation of UDP-glucuronosyltransferase 2B17 (UGT2B17) and dihydrofolate reductase (DHFR) genes deletion and the expression level of NGX6 mRNA in breast tumor. Mol Biol Rep 39(12): 10531–9.
[23]
Angstadt AY, Berg A, Zhu J, Miller P, Hartman TJ, et al. (2013) The effect of copy number variation in the phase II detoxification genes UGT2B17 and UGT2B28 on colorectal tumor risk. Tumor 119(13): 2477–85.
[24]
Guo SW, Thompson EA (1992) Performing the exact test of Hardy-Weinberg proportion for multiple alleles. Biometrics 48(2): 361–72.
[25]
Midgette AS, Wong JB, Beshansky JR, Porath A, Fleming C, et al. (1994) Cost-effectiveness of streptokinase for acute myocardial infarction: A combined meta-analysis and decision analysis of the effects of infarct location and of likelihood of infarction. Med Decis Making 14(2): 108–17.
[26]
Lau J, Ioannidis JP, Schmid CH (2007) Quantitative synthesis in systematic reviews. Ann Intern Med 127(9): 820–6.
[27]
Egger M, Davey Smith G, Schneider M, Minder C (1997) Bias in meta-analysis detected by a simple, graphical test. BMJ 315(7109): 629–34.
[28]
Liu F, Liu L, Li B, Wei YG, Yan LN, et al. (2011) p73 G4C14-A4T14 polymorphism and tumor risk: a meta-analysis based on 27 case-control studies. Mutagenesis 26(4): 573–81.
[29]
Jakobsson J, Ekstr？m L, Inotsume N, Garle M, Lorentzon M, et al. (2006) Large differences in testosterone excretion in Korean and Swedish men are strongly associated with a UDP-glucuronosyl transferase 2B17 polymorphism. J Clin Endocrinol Metab 91(2): 687–93.
[30]
Lea IA, Jackson MA, Li X, Bailey S, Peddada SD, et al. (2007) Genetic pathways and mutation profiles of human tumors: site- and exposure-specific patterns. Carcinogenesis 28(9): 1851–8.
[31]
Marin MC, Jost CA, Brooks LA, Irwin MS, ONions J, et al. (2000) A common polymorphism acts as an intragenic modifier of mutant p53 behaviour. Nat Genet 25(1): 47–54.
[32]
Amira N, Mourah S, Rozet F, Teillac P, Fiet J, et al. (2002) Non-invasive molecular detection of bladder tumor recurrence. Int J Tumor 101(3): 293–7.
[33]
Benhamou S, Lee WJ, Alexandrie AK, Boffetta P, Bouchardy C, et al. (2002) Meta- and pooled analyses of the effects of glutathione S-transferase M1 polymorphisms and smoking on lung tumor risk. Carcinogenesis 23(8): 1343–50.
[34]
Liu F, Yuan D, Wei Y, Wang W, Yan L, et al. (2012) Systematic review and meta-analysis of the relationship between EPHX1 polymorphisms and colorectal tumor risk. PLoS One 7(8): e43821.
[35]
Cai L, Huang W, Chou KC (2012) Prostate tumor with variants in CYP17 and UGT2B17 genes: a meta-analysis. Protein Pept Lett 19(1): 62–9.
